Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Antidiabetic Drug market report explains the definition, types, applications, major countries, and major players of the Antidiabetic Drug market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Eli Lilly
Boehringer Ingelheim
Bristol-Myers Squibb
Takeda
Pfizer
Novo Nordisk
Oramed
Biocon
Wockhardt
Sanofi-Aventis
Halozyme Therapeutics
Tonghua Dongbao
By Type:
Oral (eg oral hypoglycemic)
Intravenously (eg insulin and GLP-1 receptor agonists)
By End-User:
Diabetes Type 1
Diabetes Type 2
Other Types
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Antidiabetic Drug Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Antidiabetic Drug Outlook to 2028- Original Forecasts
-
2.2 Antidiabetic Drug Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Antidiabetic Drug Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Antidiabetic Drug Market- Recent Developments
-
6.1 Antidiabetic Drug Market News and Developments
-
6.2 Antidiabetic Drug Market Deals Landscape
7 Antidiabetic Drug Raw Materials and Cost Structure Analysis
-
7.1 Antidiabetic Drug Key Raw Materials
-
7.2 Antidiabetic Drug Price Trend of Key Raw Materials
-
7.3 Antidiabetic Drug Key Suppliers of Raw Materials
-
7.4 Antidiabetic Drug Market Concentration Rate of Raw Materials
-
7.5 Antidiabetic Drug Cost Structure Analysis
-
7.5.1 Antidiabetic Drug Raw Materials Analysis
-
7.5.2 Antidiabetic Drug Labor Cost Analysis
-
7.5.3 Antidiabetic Drug Manufacturing Expenses Analysis
8 Global Antidiabetic Drug Import and Export Analysis (Top 10 Countries)
-
8.1 Global Antidiabetic Drug Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Antidiabetic Drug Export by Region (Top 10 Countries) (2017-2028)
9 Global Antidiabetic Drug Market Outlook by Types and Applications to 2022
-
9.1 Global Antidiabetic Drug Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Oral (eg oral hypoglycemic) Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Intravenously (eg insulin and GLP-1 receptor agonists) Consumption and Growth Rate (2017-2022)
-
9.2 Global Antidiabetic Drug Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Diabetes Type 1 Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Diabetes Type 2 Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Other Types Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Antidiabetic Drug Market Analysis and Outlook till 2022
-
10.1 Global Antidiabetic Drug Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Antidiabetic Drug Consumption (2017-2022)
-
10.2.2 Canada Antidiabetic Drug Consumption (2017-2022)
-
10.2.3 Mexico Antidiabetic Drug Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Antidiabetic Drug Consumption (2017-2022)
-
10.3.2 UK Antidiabetic Drug Consumption (2017-2022)
-
10.3.3 Spain Antidiabetic Drug Consumption (2017-2022)
-
10.3.4 Belgium Antidiabetic Drug Consumption (2017-2022)
-
10.3.5 France Antidiabetic Drug Consumption (2017-2022)
-
10.3.6 Italy Antidiabetic Drug Consumption (2017-2022)
-
10.3.7 Denmark Antidiabetic Drug Consumption (2017-2022)
-
10.3.8 Finland Antidiabetic Drug Consumption (2017-2022)
-
10.3.9 Norway Antidiabetic Drug Consumption (2017-2022)
-
10.3.10 Sweden Antidiabetic Drug Consumption (2017-2022)
-
10.3.11 Poland Antidiabetic Drug Consumption (2017-2022)
-
10.3.12 Russia Antidiabetic Drug Consumption (2017-2022)
-
10.3.13 Turkey Antidiabetic Drug Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Antidiabetic Drug Consumption (2017-2022)
-
10.4.2 Japan Antidiabetic Drug Consumption (2017-2022)
-
10.4.3 India Antidiabetic Drug Consumption (2017-2022)
-
10.4.4 South Korea Antidiabetic Drug Consumption (2017-2022)
-
10.4.5 Pakistan Antidiabetic Drug Consumption (2017-2022)
-
10.4.6 Bangladesh Antidiabetic Drug Consumption (2017-2022)
-
10.4.7 Indonesia Antidiabetic Drug Consumption (2017-2022)
-
10.4.8 Thailand Antidiabetic Drug Consumption (2017-2022)
-
10.4.9 Singapore Antidiabetic Drug Consumption (2017-2022)
-
10.4.10 Malaysia Antidiabetic Drug Consumption (2017-2022)
-
10.4.11 Philippines Antidiabetic Drug Consumption (2017-2022)
-
10.4.12 Vietnam Antidiabetic Drug Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Antidiabetic Drug Consumption (2017-2022)
-
10.5.2 Colombia Antidiabetic Drug Consumption (2017-2022)
-
10.5.3 Chile Antidiabetic Drug Consumption (2017-2022)
-
10.5.4 Argentina Antidiabetic Drug Consumption (2017-2022)
-
10.5.5 Venezuela Antidiabetic Drug Consumption (2017-2022)
-
10.5.6 Peru Antidiabetic Drug Consumption (2017-2022)
-
10.5.7 Puerto Rico Antidiabetic Drug Consumption (2017-2022)
-
10.5.8 Ecuador Antidiabetic Drug Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Antidiabetic Drug Consumption (2017-2022)
-
10.6.2 Kuwait Antidiabetic Drug Consumption (2017-2022)
-
10.6.3 Oman Antidiabetic Drug Consumption (2017-2022)
-
10.6.4 Qatar Antidiabetic Drug Consumption (2017-2022)
-
10.6.5 Saudi Arabia Antidiabetic Drug Consumption (2017-2022)
-
10.6.6 United Arab Emirates Antidiabetic Drug Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Antidiabetic Drug Consumption (2017-2022)
-
10.7.2 South Africa Antidiabetic Drug Consumption (2017-2022)
-
10.7.3 Egypt Antidiabetic Drug Consumption (2017-2022)
-
10.7.4 Algeria Antidiabetic Drug Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Antidiabetic Drug Consumption (2017-2022)
-
10.8.2 New Zealand Antidiabetic Drug Consumption (2017-2022)
11 Global Antidiabetic Drug Competitive Analysis
-
11.1 Eli Lilly
-
11.1.1 Eli Lilly Company Details
-
11.1.2 Eli Lilly Antidiabetic Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Eli Lilly Antidiabetic Drug Main Business and Markets Served
-
11.1.4 Eli Lilly Antidiabetic Drug Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Boehringer Ingelheim
-
11.2.1 Boehringer Ingelheim Company Details
-
11.2.2 Boehringer Ingelheim Antidiabetic Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Boehringer Ingelheim Antidiabetic Drug Main Business and Markets Served
-
11.2.4 Boehringer Ingelheim Antidiabetic Drug Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Bristol-Myers Squibb
-
11.3.1 Bristol-Myers Squibb Company Details
-
11.3.2 Bristol-Myers Squibb Antidiabetic Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Bristol-Myers Squibb Antidiabetic Drug Main Business and Markets Served
-
11.3.4 Bristol-Myers Squibb Antidiabetic Drug Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 Takeda
-
11.4.1 Takeda Company Details
-
11.4.2 Takeda Antidiabetic Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 Takeda Antidiabetic Drug Main Business and Markets Served
-
11.4.4 Takeda Antidiabetic Drug Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Pfizer
-
11.5.1 Pfizer Company Details
-
11.5.2 Pfizer Antidiabetic Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Pfizer Antidiabetic Drug Main Business and Markets Served
-
11.5.4 Pfizer Antidiabetic Drug Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 Novo Nordisk
-
11.6.1 Novo Nordisk Company Details
-
11.6.2 Novo Nordisk Antidiabetic Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 Novo Nordisk Antidiabetic Drug Main Business and Markets Served
-
11.6.4 Novo Nordisk Antidiabetic Drug Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 Oramed
-
11.7.1 Oramed Company Details
-
11.7.2 Oramed Antidiabetic Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 Oramed Antidiabetic Drug Main Business and Markets Served
-
11.7.4 Oramed Antidiabetic Drug Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 Biocon
-
11.8.1 Biocon Company Details
-
11.8.2 Biocon Antidiabetic Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 Biocon Antidiabetic Drug Main Business and Markets Served
-
11.8.4 Biocon Antidiabetic Drug Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 Wockhardt
-
11.9.1 Wockhardt Company Details
-
11.9.2 Wockhardt Antidiabetic Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 Wockhardt Antidiabetic Drug Main Business and Markets Served
-
11.9.4 Wockhardt Antidiabetic Drug Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 Sanofi-Aventis
-
11.10.1 Sanofi-Aventis Company Details
-
11.10.2 Sanofi-Aventis Antidiabetic Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 Sanofi-Aventis Antidiabetic Drug Main Business and Markets Served
-
11.10.4 Sanofi-Aventis Antidiabetic Drug Product Portfolio
-
11.10.5 Recent Research and Development Strategies
-
11.11 Halozyme Therapeutics
-
11.11.1 Halozyme Therapeutics Company Details
-
11.11.2 Halozyme Therapeutics Antidiabetic Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.11.3 Halozyme Therapeutics Antidiabetic Drug Main Business and Markets Served
-
11.11.4 Halozyme Therapeutics Antidiabetic Drug Product Portfolio
-
11.11.5 Recent Research and Development Strategies
-
11.12 Tonghua Dongbao
-
11.12.1 Tonghua Dongbao Company Details
-
11.12.2 Tonghua Dongbao Antidiabetic Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.12.3 Tonghua Dongbao Antidiabetic Drug Main Business and Markets Served
-
11.12.4 Tonghua Dongbao Antidiabetic Drug Product Portfolio
-
11.12.5 Recent Research and Development Strategies
12 Global Antidiabetic Drug Market Outlook by Types and Applications to 2028
-
12.1 Global Antidiabetic Drug Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Oral (eg oral hypoglycemic) Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Intravenously (eg insulin and GLP-1 receptor agonists) Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Antidiabetic Drug Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Diabetes Type 1 Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Diabetes Type 2 Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Other Types Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Antidiabetic Drug Market Analysis and Outlook to 2028
-
13.1 Global Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.2.2 Canada Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.2.3 Mexico Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.3.2 UK Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.3.3 Spain Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.3.4 Belgium Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.3.5 France Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.3.6 Italy Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.3.7 Denmark Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.3.8 Finland Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.3.9 Norway Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.3.10 Sweden Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.3.11 Poland Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.3.12 Russia Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.3.13 Turkey Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.4.2 Japan Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.4.3 India Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.4.4 South Korea Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.4.8 Thailand Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.4.9 Singapore Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.4.11 Philippines Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.5.2 Colombia Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.5.3 Chile Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.5.4 Argentina Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.5.6 Peru Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.6.3 Oman Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.6.4 Qatar Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.7.2 South Africa Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.7.3 Egypt Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.7.4 Algeria Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Antidiabetic Drug Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Antidiabetic Drug Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Antidiabetic Drug
-
Figure of Antidiabetic Drug Picture
-
Table Global Antidiabetic Drug Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Antidiabetic Drug Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Oral (eg oral hypoglycemic) Consumption and Growth Rate (2017-2022)
-
Figure Global Intravenously (eg insulin and GLP-1 receptor agonists) Consumption and Growth Rate (2017-2022)
-
Figure Global Diabetes Type 1 Consumption and Growth Rate (2017-2022)
-
Figure Global Diabetes Type 2 Consumption and Growth Rate (2017-2022)
-
Figure Global Other Types Consumption and Growth Rate (2017-2022)
-
Figure Global Antidiabetic Drug Consumption by Country (2017-2022)
-
Table North America Antidiabetic Drug Consumption by Country (2017-2022)
-
Figure United States Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure Canada Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure Mexico Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Table Europe Antidiabetic Drug Consumption by Country (2017-2022)
-
Figure Germany Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure UK Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure Spain Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure Belgium Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure France Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure Italy Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure Denmark Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure Finland Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure Norway Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure Sweden Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure Poland Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure Russia Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure Turkey Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Table APAC Antidiabetic Drug Consumption by Country (2017-2022)
-
Figure China Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure Japan Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure India Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure South Korea Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure Thailand Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure Singapore Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure Philippines Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Table South America Antidiabetic Drug Consumption by Country (2017-2022)
-
Figure Brazil Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure Colombia Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure Chile Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure Argentina Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure Peru Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Table GCC Antidiabetic Drug Consumption by Country (2017-2022)
-
Figure Bahrain Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure Oman Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure Qatar Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Table Africa Antidiabetic Drug Consumption by Country (2017-2022)
-
Figure Nigeria Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure South Africa Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure Egypt Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure Algeria Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Table Oceania Antidiabetic Drug Consumption by Country (2017-2022)
-
Figure Australia Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Antidiabetic Drug Consumption and Growth Rate (2017-2022)
-
Table Eli Lilly Company Details
-
Table Eli Lilly Antidiabetic Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Eli Lilly Antidiabetic Drug Main Business and Markets Served
-
Table Eli Lilly Antidiabetic Drug Product Portfolio
-
Table Boehringer Ingelheim Company Details
-
Table Boehringer Ingelheim Antidiabetic Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Boehringer Ingelheim Antidiabetic Drug Main Business and Markets Served
-
Table Boehringer Ingelheim Antidiabetic Drug Product Portfolio
-
Table Bristol-Myers Squibb Company Details
-
Table Bristol-Myers Squibb Antidiabetic Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bristol-Myers Squibb Antidiabetic Drug Main Business and Markets Served
-
Table Bristol-Myers Squibb Antidiabetic Drug Product Portfolio
-
Table Takeda Company Details
-
Table Takeda Antidiabetic Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Takeda Antidiabetic Drug Main Business and Markets Served
-
Table Takeda Antidiabetic Drug Product Portfolio
-
Table Pfizer Company Details
-
Table Pfizer Antidiabetic Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer Antidiabetic Drug Main Business and Markets Served
-
Table Pfizer Antidiabetic Drug Product Portfolio
-
Table Novo Nordisk Company Details
-
Table Novo Nordisk Antidiabetic Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novo Nordisk Antidiabetic Drug Main Business and Markets Served
-
Table Novo Nordisk Antidiabetic Drug Product Portfolio
-
Table Oramed Company Details
-
Table Oramed Antidiabetic Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Oramed Antidiabetic Drug Main Business and Markets Served
-
Table Oramed Antidiabetic Drug Product Portfolio
-
Table Biocon Company Details
-
Table Biocon Antidiabetic Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Biocon Antidiabetic Drug Main Business and Markets Served
-
Table Biocon Antidiabetic Drug Product Portfolio
-
Table Wockhardt Company Details
-
Table Wockhardt Antidiabetic Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Wockhardt Antidiabetic Drug Main Business and Markets Served
-
Table Wockhardt Antidiabetic Drug Product Portfolio
-
Table Sanofi-Aventis Company Details
-
Table Sanofi-Aventis Antidiabetic Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Sanofi-Aventis Antidiabetic Drug Main Business and Markets Served
-
Table Sanofi-Aventis Antidiabetic Drug Product Portfolio
-
Table Halozyme Therapeutics Company Details
-
Table Halozyme Therapeutics Antidiabetic Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Halozyme Therapeutics Antidiabetic Drug Main Business and Markets Served
-
Table Halozyme Therapeutics Antidiabetic Drug Product Portfolio
-
Table Tonghua Dongbao Company Details
-
Table Tonghua Dongbao Antidiabetic Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Tonghua Dongbao Antidiabetic Drug Main Business and Markets Served
-
Table Tonghua Dongbao Antidiabetic Drug Product Portfolio
-
Figure Global Oral (eg oral hypoglycemic) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Intravenously (eg insulin and GLP-1 receptor agonists) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Diabetes Type 1 Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Diabetes Type 2 Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Other Types Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Antidiabetic Drug Consumption Forecast by Country (2022-2028)
-
Table North America Antidiabetic Drug Consumption Forecast by Country (2022-2028)
-
Figure United States Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Antidiabetic Drug Consumption Forecast by Country (2022-2028)
-
Figure Germany Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Antidiabetic Drug Consumption Forecast by Country (2022-2028)
-
Figure China Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Antidiabetic Drug Consumption Forecast by Country (2022-2028)
-
Figure Brazil Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Antidiabetic Drug Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Antidiabetic Drug Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Antidiabetic Drug Consumption Forecast by Country (2022-2028)
-
Figure Australia Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Antidiabetic Drug Consumption Forecast and Growth Rate (2022-2028)
-
